Allergan Plc (AGN) 240.93 $AGN
Dr. Reddy's to acquire product portfolio from TEVA for US Market
BusinessWire - Sat Jun 11, 8:26AM CDT
Dr. Reddy's Laboratories (BSE:500124, NSE
RREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and an affiliate of Allergan plc (NYSE:AGN)to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the U.S. for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics transaction and approval by the U.S. Federal Trade Commission of Dr. Reddy's as a buyer.
AGN: 240.93 (-6.47), RDY: 45.10 (-0.69)
Look for Shares of Allergan to Potentially Rebound after Yesterday's 1.68% Sell Off
Comtex SmarTrend(R) - Fri Jun 10, 12:03PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $242.90 to a high of $245.85. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $243.06 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 240.93 (-6.47)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 240.93 (-6.47), IRWD: 12.87 (-0.13), AZN: 27.97 (-0.99), JNP: 6.91 (-0.06)
Study Reveals Gender Differences in Migraine Treatment
PR Newswire - Fri Jun 10, 7:31AM CDT
DUBLIN, June 10, 2016 /PRNewswire/-- Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that new data presented at the American Headache Society (AHS) annual scientific meeting reveals differences between the way men and women react to migraines, suggesting underlying disparities in headache characteristics and progression.i The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study longitudinally explored the causes and burden of Chronic Migraine and Episodic Migraine, both part of the spectrum of migraine disorders but distinct clinical entities. Chronic Migraine is a neurological condition characterized by 15 or more headache days per month, with headaches lasting four hours a day or longer, and at least eight of those headache days being associated with migraine, while Episodic Migraine is defined as less than 15 headache days per month.ii
AGN: 240.93 (-6.47)
ActuallySheCan(SM) By Allergan Launches Limited Edition #ActuallySheCan(SM) Tank Top Shirts, A Charitable Initiative Supporting Military Women
PR Newswire - Thu Jun 09, 7:31AM CDT
ActuallySheCanSM, the inspiring female empowerment campaign by Allergan, a leader in women's healthcare, is proud to announce the release of limited edition #ActuallySheCan Tanks created in partnership with lifestyle brand, Le Motto(TM).
AGN: 240.93 (-6.47)
Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
PR Newswire - Thu Jun 09, 7:01AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the 72 mcg dose of linaclotide for use in the treatment of adults with chronic idiopathic constipation (CIC). The sNDA for the 72 mcg dose of linaclotide is based on efficacy and safety data from a double-blind, placebo-controlled Phase III clinical trial of 1,223 adult patients with CIC. The FDA Prescription Drug User Fee Act (PDUFA) target action date is expected to occur in early 2017.
AGN: 240.93 (-6.47), IRWD: 12.87 (-0.13)
Prospect Park Capital Announces Investee News and Results of AGM
Marketwired - Wed Jun 08, 5:21PM CDT
TORONTO, ONTARIO--(Marketwired - Jun 8, 2016) - Prospect Park Capital Corp. ("Prospect Park"
(TSX VENTURE
PK), a public healthcare focused investment corporation, announces that one of its investees, IOI, LLC ("IOI", has been advised by Serenity Pharmaceuticals, LLC ("Serenity" that after the requisite 60 days for examination, the US Food & Drug Administration ("FDA" has accepted Serenity's new drug application (NDA) submitted on February 4, 2016. As a consequence of the acceptance of the NDA application, Allergan, PPL, per contractual obligation, provided Serenity with a US$22 million milestone payment. Prospect Park is entitled to a milestone payment equal to US$48,000 (32% of its initial investment in IOI) should the Serenity nocturia drug successfully receive approval by the FDA.
AGN: 240.93 (-6.47), PPK.VN: 0.025 (-0.005)
Covered Call Alerts For Apple, Activision Blizzard, Allergan, Google Inc. and Computer Sciences Corporation Released By InvestorsObserver
PR Newswire - Wed Jun 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ATVI, AGN, GOOG and CSC.
AGN: 240.93 (-6.47), ATVI: 37.77 (-0.77), CSC: 51.65 (-0.85), GOOGL: 733.19 (-9.33), GOOG: 719.41 (-9.17), AAPL: 98.83 (-0.82)
Global Anti-Aging Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Allergan, L'Oreal, Unilever - Research and Markets
BusinessWire - Wed Jun 08, 6:56AM CDT
Research and Markets has announced the addition of the "Global Anti-Aging Market Report and Forecast (2016-2021)" report to their offering.
AGN: 240.93 (-6.47)
The Allergan Foundation And The Jed Foundation Announce Three-Year $300,000 Scholarship Fund To Support JED Campus Program
PR Newswire - Wed Jun 08, 6:30AM CDT
The Allergan Foundation, a U.S.-based private charitable foundation endowed by Allergan plc, today announced that it will provide a three-year, $300,000 scholarship commitment to support The Jed Foundation's JED Campus Program, a nationwide initiative designed to empower schools with customized support to enhance student mental health and improve substance abuse and suicide prevention efforts. The scholarship fund was created to ensure that schools with limited resources can access the JED Campus Program and build effective and sustainable mental health safety nets to support student well-being.
AGN: 240.93 (-6.47)
Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Allergan, Pfizer, ICStudy - Research and Markets
BusinessWire - Wed Jun 08, 3:39AM CDT
Research and Markets has announced the addition of the "Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
AGN: 240.93 (-6.47)
Chase Pharmaceuticals Continues to Build Its Senior Leadership Team with Appointment of Two Healthcare Industry Veterans
BusinessWire - Mon Jun 06, 4:02PM CDT
Chase Pharmaceuticals Corporation (Chase), a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders including Alzheimer's disease, announced today the expansion of its senior management team with the appointments of Scott M. Giacobello as chief financial officer and Gary Charbonneau as senior vice president, regulatory affairs and operations. These additions bring significant industry experience to the executive bench as Chase prepares to commence its Phase 3 clinical trial later this year with CPC 201 - an innovative new treatment for Alzheimer's disease. These hires underscore the company's commitment to address the growing urgency for significantly improved Alzheimer's therapies through an elegant development approach that is efficient, fast and largely de-risked.
AGN: 240.93 (-6.47)
Kate Bosworth Partners with Allergan to Celebrate Launch of ACZONE® (dapsone) Gel, 7.5% in New York City
PR Newswire - Mon Jun 06, 7:31AM CDT
Actress, producer and model Kate Bosworth is partnering with Allergan plc (NYSE: AGN), a leading global pharmaceutical company, to unveil the new ACZONE® (dapsone) Gel, 7.5% and share her personal experience with acne. ACZONE® Gel, 7.5% is a new prescription topical treatment for acne in patients 12 years of age and older, with just once-a-day application.1 At an exclusive event hosted in New York City, Kate teamed up with nationally-renowned dermatologist, Joshua Zeichner, MD, to discuss the complexities behind the most common chronic skin condition in the U.S.2 and steps to help manage acne, from what goes in the body to what goes on the skin.
AGN: 240.93 (-6.47)
Ebix's A.D.A.M. Division Wins Communicator Award for Excellence
Marketwired - Mon Jun 06, 7:30AM CDT
JOHNS CREEK, GA--(Marketwired - Jun 6, 2016) - Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of on-demand software and e-commerce services to the insurance, financial and healthcare industries announced today that its A.D.A.M. Division's creative work has won the Communicator Award in 2016 for its E-learning tool built for Allergan, one of the leaders in the pharmaceutical industry. Founded two decades ago, The Communicator Awards by the International Academy of the Visual Arts receive over 6,000 entries from companies and agencies of all sizes, making it one of the largest awards of its kind in the world.
AGN: 240.93 (-6.47), EBIX: 47.35 (-1.55)
Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
PR Newswire - Mon Jun 06, 6:31AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the approval of BYVALSON(TM) (nebivolol and valsartan) 5 mg/ 80 mg tablets, by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension to lower blood pressure. BYVALSON is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the U.S.
AGN: 240.93 (-6.47)
Stock Market News for June 03, 2016
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:10AM CDT
Benchmarks finished in the green on Thursday following encouraging U.S. private sector jobs data and gains in healthcare stocks
AGN: 240.93 (-6.47), JNJ: 117.01 (+0.01), ADP: 87.09 (-0.54), MDT: 85.70 (-0.08), PFE: 35.29 (-0.02), MRK: 56.81 (-0.37), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), BMY: 72.65 (-0.08), AET: 120.52 (-0.75), HUM: 186.76 (-1.59)
Covered Call reports for Facebook, Exxon Mobil, Lululemon, Allergan, and Chevron include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Jun 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FB, XOM, LULU, AGN and CVX.
AGN: 240.93 (-6.47), FB: 116.62 (-1.94), XOM: 89.98 (-0.69), CVX: 101.98 (-0.83), LULU: 70.54 (-1.78)
Clarification: Financial Markets-Stocks story
AP - Wed Jun 01, 1:36PM CDT
NEW YORK (AP) — In a story May 31, The Associated Press described the drug Zinbryta as belonging to Biogen. The drug is being developed and promoted by Biogen and AbbVie.
CPXX: 30.24 (+0.08), AGN: 240.93 (-6.47), WR: 56.37 (+0.26), CLX: 131.77 (+0.86), MDT: 85.70 (-0.08), BA: 131.14 (-1.96)
Dr. Reddy's to acquire product portfolio from TEVA for US Market
BusinessWire - Sat Jun 11, 8:26AM CDT
Dr. Reddy's Laboratories (BSE:500124, NSE
RREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and an affiliate of Allergan plc (NYSE:AGN)to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the U.S. for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics transaction and approval by the U.S. Federal Trade Commission of Dr. Reddy's as a buyer. AGN: 240.93 (-6.47), RDY: 45.10 (-0.69)
Look for Shares of Allergan to Potentially Rebound after Yesterday's 1.68% Sell Off
Comtex SmarTrend(R) - Fri Jun 10, 12:03PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $242.90 to a high of $245.85. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $243.06 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 240.93 (-6.47)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 240.93 (-6.47), IRWD: 12.87 (-0.13), AZN: 27.97 (-0.99), JNP: 6.91 (-0.06)
Study Reveals Gender Differences in Migraine Treatment
PR Newswire - Fri Jun 10, 7:31AM CDT
DUBLIN, June 10, 2016 /PRNewswire/-- Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that new data presented at the American Headache Society (AHS) annual scientific meeting reveals differences between the way men and women react to migraines, suggesting underlying disparities in headache characteristics and progression.i The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study longitudinally explored the causes and burden of Chronic Migraine and Episodic Migraine, both part of the spectrum of migraine disorders but distinct clinical entities. Chronic Migraine is a neurological condition characterized by 15 or more headache days per month, with headaches lasting four hours a day or longer, and at least eight of those headache days being associated with migraine, while Episodic Migraine is defined as less than 15 headache days per month.ii
AGN: 240.93 (-6.47)
ActuallySheCan(SM) By Allergan Launches Limited Edition #ActuallySheCan(SM) Tank Top Shirts, A Charitable Initiative Supporting Military Women
PR Newswire - Thu Jun 09, 7:31AM CDT
ActuallySheCanSM, the inspiring female empowerment campaign by Allergan, a leader in women's healthcare, is proud to announce the release of limited edition #ActuallySheCan Tanks created in partnership with lifestyle brand, Le Motto(TM).
AGN: 240.93 (-6.47)
Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
PR Newswire - Thu Jun 09, 7:01AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the 72 mcg dose of linaclotide for use in the treatment of adults with chronic idiopathic constipation (CIC). The sNDA for the 72 mcg dose of linaclotide is based on efficacy and safety data from a double-blind, placebo-controlled Phase III clinical trial of 1,223 adult patients with CIC. The FDA Prescription Drug User Fee Act (PDUFA) target action date is expected to occur in early 2017.
AGN: 240.93 (-6.47), IRWD: 12.87 (-0.13)
Prospect Park Capital Announces Investee News and Results of AGM
Marketwired - Wed Jun 08, 5:21PM CDT
TORONTO, ONTARIO--(Marketwired - Jun 8, 2016) - Prospect Park Capital Corp. ("Prospect Park"
(TSX VENTUREPK), a public healthcare focused investment corporation, announces that one of its investees, IOI, LLC ("IOI", has been advised by Serenity Pharmaceuticals, LLC ("Serenity" that after the requisite 60 days for examination, the US Food & Drug Administration ("FDA" has accepted Serenity's new drug application (NDA) submitted on February 4, 2016. As a consequence of the acceptance of the NDA application, Allergan, PPL, per contractual obligation, provided Serenity with a US$22 million milestone payment. Prospect Park is entitled to a milestone payment equal to US$48,000 (32% of its initial investment in IOI) should the Serenity nocturia drug successfully receive approval by the FDA. AGN: 240.93 (-6.47), PPK.VN: 0.025 (-0.005)
Covered Call Alerts For Apple, Activision Blizzard, Allergan, Google Inc. and Computer Sciences Corporation Released By InvestorsObserver
PR Newswire - Wed Jun 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ATVI, AGN, GOOG and CSC.
AGN: 240.93 (-6.47), ATVI: 37.77 (-0.77), CSC: 51.65 (-0.85), GOOGL: 733.19 (-9.33), GOOG: 719.41 (-9.17), AAPL: 98.83 (-0.82)
Global Anti-Aging Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Allergan, L'Oreal, Unilever - Research and Markets
BusinessWire - Wed Jun 08, 6:56AM CDT
Research and Markets has announced the addition of the "Global Anti-Aging Market Report and Forecast (2016-2021)" report to their offering.
AGN: 240.93 (-6.47)
The Allergan Foundation And The Jed Foundation Announce Three-Year $300,000 Scholarship Fund To Support JED Campus Program
PR Newswire - Wed Jun 08, 6:30AM CDT
The Allergan Foundation, a U.S.-based private charitable foundation endowed by Allergan plc, today announced that it will provide a three-year, $300,000 scholarship commitment to support The Jed Foundation's JED Campus Program, a nationwide initiative designed to empower schools with customized support to enhance student mental health and improve substance abuse and suicide prevention efforts. The scholarship fund was created to ensure that schools with limited resources can access the JED Campus Program and build effective and sustainable mental health safety nets to support student well-being.
AGN: 240.93 (-6.47)
Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Allergan, Pfizer, ICStudy - Research and Markets
BusinessWire - Wed Jun 08, 3:39AM CDT
Research and Markets has announced the addition of the "Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
AGN: 240.93 (-6.47)
Chase Pharmaceuticals Continues to Build Its Senior Leadership Team with Appointment of Two Healthcare Industry Veterans
BusinessWire - Mon Jun 06, 4:02PM CDT
Chase Pharmaceuticals Corporation (Chase), a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders including Alzheimer's disease, announced today the expansion of its senior management team with the appointments of Scott M. Giacobello as chief financial officer and Gary Charbonneau as senior vice president, regulatory affairs and operations. These additions bring significant industry experience to the executive bench as Chase prepares to commence its Phase 3 clinical trial later this year with CPC 201 - an innovative new treatment for Alzheimer's disease. These hires underscore the company's commitment to address the growing urgency for significantly improved Alzheimer's therapies through an elegant development approach that is efficient, fast and largely de-risked.
AGN: 240.93 (-6.47)
Kate Bosworth Partners with Allergan to Celebrate Launch of ACZONE® (dapsone) Gel, 7.5% in New York City
PR Newswire - Mon Jun 06, 7:31AM CDT
Actress, producer and model Kate Bosworth is partnering with Allergan plc (NYSE: AGN), a leading global pharmaceutical company, to unveil the new ACZONE® (dapsone) Gel, 7.5% and share her personal experience with acne. ACZONE® Gel, 7.5% is a new prescription topical treatment for acne in patients 12 years of age and older, with just once-a-day application.1 At an exclusive event hosted in New York City, Kate teamed up with nationally-renowned dermatologist, Joshua Zeichner, MD, to discuss the complexities behind the most common chronic skin condition in the U.S.2 and steps to help manage acne, from what goes in the body to what goes on the skin.
AGN: 240.93 (-6.47)
Ebix's A.D.A.M. Division Wins Communicator Award for Excellence
Marketwired - Mon Jun 06, 7:30AM CDT
JOHNS CREEK, GA--(Marketwired - Jun 6, 2016) - Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of on-demand software and e-commerce services to the insurance, financial and healthcare industries announced today that its A.D.A.M. Division's creative work has won the Communicator Award in 2016 for its E-learning tool built for Allergan, one of the leaders in the pharmaceutical industry. Founded two decades ago, The Communicator Awards by the International Academy of the Visual Arts receive over 6,000 entries from companies and agencies of all sizes, making it one of the largest awards of its kind in the world.
AGN: 240.93 (-6.47), EBIX: 47.35 (-1.55)
Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
PR Newswire - Mon Jun 06, 6:31AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the approval of BYVALSON(TM) (nebivolol and valsartan) 5 mg/ 80 mg tablets, by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension to lower blood pressure. BYVALSON is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the U.S.
AGN: 240.93 (-6.47)
Stock Market News for June 03, 2016
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:10AM CDT
Benchmarks finished in the green on Thursday following encouraging U.S. private sector jobs data and gains in healthcare stocks
AGN: 240.93 (-6.47), JNJ: 117.01 (+0.01), ADP: 87.09 (-0.54), MDT: 85.70 (-0.08), PFE: 35.29 (-0.02), MRK: 56.81 (-0.37), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), BMY: 72.65 (-0.08), AET: 120.52 (-0.75), HUM: 186.76 (-1.59)
Covered Call reports for Facebook, Exxon Mobil, Lululemon, Allergan, and Chevron include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Jun 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FB, XOM, LULU, AGN and CVX.
AGN: 240.93 (-6.47), FB: 116.62 (-1.94), XOM: 89.98 (-0.69), CVX: 101.98 (-0.83), LULU: 70.54 (-1.78)
Clarification: Financial Markets-Stocks story
AP - Wed Jun 01, 1:36PM CDT
NEW YORK (AP) — In a story May 31, The Associated Press described the drug Zinbryta as belonging to Biogen. The drug is being developed and promoted by Biogen and AbbVie.
CPXX: 30.24 (+0.08), AGN: 240.93 (-6.47), WR: 56.37 (+0.26), CLX: 131.77 (+0.86), MDT: 85.70 (-0.08), BA: 131.14 (-1.96)
